Member Info for Leggster

HBD, I agree we are clearly moving forward and the SP is disconnected with progress, yes would be supportive of a raise for funding if no deal available at a decent level from the 1a results once data is available to share with potential partners. All to play for still. GLA

Well very turbulent and I certainly did not expect a drop on good news. However we inch closer to finishing 1a hopefully news on MAD in another few weeks and some more insight on 737 at some point. For me the price is currently misaligned to progress. I am still supportive of the board who also are shareholders and have also been hit by this drop, patience is required and a steady nerve. My only real concern is a TO that does not adequately recognise the value of the company. Let's hope for some buying in the next week. GLA

Fantastic news this morning, onwards and upwards for all three molecules today and we should not discount the value this also adds to 1802. GLA

All very down beat here current and very understandable given the share price falls. But news can arrive quickly, could get news any time on the completion of 1a and the start of reviewing data and more 737 news could also be released. I'm waiting for the morning we wake to some positive update and still have confidence of a good return. GLA

This is also the narrative that I favour at this time, I would expect the BOD to be talking to interested parties in advance of safety data being available. Once available I believe interested parties will review and I suspect we will see an agreement before 1b completes. Its a hard waiting period with this drop but we are very deep in trials and more news from 737 must drop at some point.

GLA

The RF deal has not been great but its a hell of a lot better than the position RENE announced yesterday. We are still in business and not likely to have our patents snapped up at bargain basement prices. GLA

All who invest here should know this is high risk high reward. All investors should have done their homework before commiting their hard earned cash. If this does what I believe it has a high probability to do we will hopefully all be happy. If it fails, which could happen, you have to be prepared to take that. IMO we are deep in trial with no bad news, 737 has another deal, 1802 is in the the wings. I feel the positives outweigh the negatives and feel this will come good. Exit strategy is the difficult call. GLA DYOR

Possibly a structure could be a licence but with the licencee also taking an equity stake in SAR to allow future TO should 1801/2 pass future trials....this could resolve concerns on SARs part of a TO on the cheap at this time but protect the licencee against heavy future royalty payments after success in Phase 3..

Laz and Potnak, thanks for the comments, I personally agree that Tim and John's preferred exit plan based on stage of life would be a TO, however with the SP in its current range I don't think they would accept what might be on offer. I feel a licence for 1801 is probably most likely. With a need then to move 1802 though trial, the licence might cover that cost but could then be in a similar situation to now albeit at higher levels, so price spiking on news then slipping. That was what prompted my thoughts on dual listing which could create some stability on the SP, extra fund raising for 1802 (or other projects) from new investors and an improved return in the mid term for PI's. For the record though a TO at a strong price is my real preference, I am not though convinced fair value would be obtained at this time. GLA

Many of us are frustrated by the performance of the SP on the AIM. Let's assume for a moment that the 1801 trial is a success and we get a decent deal but not a T/O. Would anyone favour at that time going for a dual listing on the NASDAQ? Clearly there are costs, stricter corporate governance, GAPP compliance, some US presence, with SARs small size probably would need to start on the Nasdaq First North Growth Market rather than the main index. But could open up new investment opportunities. Could this be a strategy to hang on to SP gains following a licence and to reduce the SP attrition we see on the AIM that would probably happen again between milestone achievements.

Looking at recent patterns I wonder if we will have some news shortly, recent patterns have been am attack on SP then buying, as we have seen today, hopefully mews incoming. GLA

Silver enjoy retirement, hopefully many others can do the same when this achieves its promise, at times it feels like a long wait but we are deep in the trial now with no negative news and 737 is back in play. Lots to be optimistic about although the wait at times is painful. GLA

This is a high risk stock all who invest here should know this, we can all have different strategies trade or hold but ultimately this is high risk. I choose to hold and buy because I see the upside as huge. Many may critise but I will trust the science. GLa

Yes despite the SP I feel far more bullish, the new 737 deal gives me some backstop confidence in a negative scenario for 1801, however 1801 in reality is deep into 1a (possibly complete) positive news on the results open the chance of early deals whilst 1b is in flight and richer deals at the end of 1b. For me far more positive than negative signs. Might buy more but definately not considering selling at this time GLA

Great news to start the year, shows the molecule still has value, delivers a line of sight to some reoccurring revenue, had hoped for a higher upfront payment but value of the shares is an unkown. Feel this is great news hoping for an announcement in due course of the partners plans. Wonder if this might be a company being setup specifically by the combo pharmas to develop the molecule in a structure that gives them some future certainty/influence on Commercialisation. Anyway can have fun speculating until the partner shows their hand. Great news very happy with the start to the year, roll on updates on 1801 as we progress through 2024. GLA

A poor 2023 for the share price, but I am looking forward to better things in 2024. One way or another this its reaching its climax. 737 should crack a deal, 1801 has had no issues yet and will complete phase 1a and b, 1802 should be in good shape once it goes into trial, although the RF experience has not been great we are funded. My personal preference is a takeover but at the current SP any offers are likely to be unacceptable low. So am hoping for a 737 deal, positive results from 1a and a nice rise in the SP and then a takeover. Still very bullish on this share and keen to see how 2024 pans out. GLA

And apologies for the typo, Laz was intended not Lazy

Lazy, I would expect some acknowledgement of the completion of 1a, SAD, MAD and Food, I personally feel if the data from 1a is good that bidding may start and a deal appear while we are carrying out 1b. Getting here with no issues is for me a huge step for 1801 (and 1802), clearly offers before 1b will be lower but still excited around the prospects. Merry Christmas and GLA

Scheckler, I did mean a positive news drop rather than the negative, I'm always an optimist and it does feel like there has been long enough now for data reviews and offers to appear, but you never know as this is the high risk high reward sector, GLA

Well the AGM was a damp squib, but no bad news, I still believe 737 will drop, 1801 continues to push onwards, 1802 will look strong once 1801 trials conclude, plenty of IP protection, slow slip of SP on no news is normal but am looking forward to a much brighter 2024 performance, the end game gets ever closer GLA